Log in
Enquire now
‌

US Patent 7989434 Heterocyclic self-immolative linkers and conjugates

Patent 7989434 was granted and assigned to Seagen on August, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Seagen
Seagen
Date Filed
April 21, 2010
Date of Patent
August 2, 2011
Patent Application Number
12764821
Patent Citations Received
‌
US Patent 12016842 Methods of using anti-CD79b immunoconjugates
0
‌
US Patent 11932650 Potent agelastatin derivatives as modulators for cancer invasion and metastasis
0
‌
US Patent 11944689 Drug conjugates with self-stabilizing linkers having improved physiochemical properties
0
‌
US Patent 11957760 Folate receptor targeted nanoparticle drug conjugates and uses thereof
0
‌
US Patent 11744897 Folate receptor targeted nanoparticle drug conjugates and uses thereof
‌
US Patent 11759527 Anti-EGFR antibody-drug conjugates
‌
US Patent 11866496 Humanized anti-CD79B antibodies and immunoconjugates and methods of use
0
‌
US Patent 11911483 Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
0
‌
US Patent 11931414 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7989434
Patent Primary Examiner
‌
Christina Bradley

Find more entities like US Patent 7989434 Heterocyclic self-immolative linkers and conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.